Spots Global Cancer Trial Database for 500mg Fulvestrant Versus Exemestane in MBC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 500mg Fulvestrant Versus Exemestane in MBC
Official Title: 500mg Fulvestrant Versus Exemestane in Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-steroidal Aromatase Inhibitors in Clinical Practice- a Multicenter Retrospective Study
Study ID: NCT03575260
Conditions
Interventions
Study Description
Brief Summary: 500mg Fulvestrant versus Exemestane in MBC
Detailed Description: 500mg Fulvestrant versus Exemestane in Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors in clinical practice- a multicenter retrospective study
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Biyun Wang, MD, Shanghai, Shanghai, China
Contact Details
Name: Biyun Wang, Professor
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
